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ABSTRACT
Werner syndrome (WS) is a premature aging disorder
that mainly affects tissues derived from mesoderm. We
have recently developed a novel human WS model
using WRN-deﬁcient human mesenchymal stem cells
(MSCs). This model recapitulates many phenotypic
features of WS. Based on a screen of a number of
chemicals, here we found that Vitamin C exerts most
efﬁcient rescue for many features in premature aging
as shown in WRN-deﬁcient MSCs, including cell
growth arrest, increased reactive oxygen species
levels, telomere attrition, excessive secretion of
inﬂammatory factors, as well as disorganization of
nuclear lamina and heterochromatin. Moreover, Vitamin
C restores in vivo viability of MSCs in a mouse model.
RNA sequencing analysis indicates that Vitamin C
alters the expression of a series of genes involved in
chromatin condensation, cell cycle regulation, DNA
replication, and DNA damage repair pathways in WRN-
deﬁcient MSCs. Our results identify Vitamin C as a
rejuvenating factor for WS MSCs, which holds the
potential of being applied as a novel type of treatment
of WS.
KEYWORDS Vitamin C, stem cell, aging, Werner
syndrome
INTRODUCTION
Aging is deﬁned as a time-dependent deterioration of
organism’s physiological functions that leads to loss of
homeostasis and consequently increases susceptibility to
morbidity and mortality (Benayoun et al., 2015; Burtner and
Kennedy, 2010; Campisi, 2013; Kudlow et al., 2007; Lopez-
Otin et al., 2013). Werner Syndrome (referred to as WS, also
known as adult progeria) is a premature aging disorder with
phenotypes such as grey hair, osteoporosis, diabetes, and
cancer. WS is caused by mutations in the WRN gene, which
is involved in several fundamental cellular mechanisms,
including DNA replication, DNA repair, and telomere
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maintenance (Burtner and Kennedy, 2010; Kudlow et al.,
2007; Lopez-Otin et al., 2013). Since the expression of WRN
also decreases during physiological aging (Polosak et al.,
2011; Zhang et al., 2015), WS may be a relevant model for
studying physiological aging and aging-associated disorders
(Burtner and Kennedy, 2010; Kudlow et al., 2007; Lopez-
Otin et al., 2013).
The advances in pluripotent stem cell and gene editing
techniques have opened a new avenue to study the
pathogenesis of human premature aging syndromes and
aging-related diseases (Fu et al., 2016; Liu et al., 2011; Liu
et al., 2012b; Liu et al., 2014; Lo Cicero and Nissan, 2015;
Miller et al., 2013; Pan et al., 2016; Zhang et al., 2015).
They also provide a powerful platform for drug screening
and validation of their efﬁcacy (Blondel et al., 2016; Liu
et al., 2012a; Liu et al., 2012b; Liu et al., 2014; Yang et al.,
2014; Zhang et al., 2013). We have recently developed a
human stem cell model by homozygous depletion of the
Plate WT-MSC or WRN-/- MSC
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Figure 1. Chemicals screening for alleviating premature aging in WS MSCs. (A) Schematic demonstration of the chemical
screening protocol. 3 × 104 wild-type (WT) or WRN-/- MSCs (P5) were seeded in one well of 6-well dish, following with the treatment
with the chemicals or vehicle control (water or DMSO) and refreshed every other day. Cell senescence, assayed by senescence
associated β-galactosidase (SA-β-gal) staining, was analyzed 1 week later. (B) Frequency of SA-β-gal positive cells in WTor WRN-/-
MSCs with or without chemical treatment. For each molecule, different concentrations were used as indicated along the X axis. Data
are represented as mean ± SEM, *P < 0.05, **P < 0.01, ***P < 0.001, NS, not signiﬁcant by t test; n ≥ 3. (C) Representative images of
SA-β-gal staining. VC: 280 µmol/L; VE: 20 µmol/L; EGCG: 2 µmol/L; NAC: 100 µmol/L; Met: 10 µmol/L; Rap: 0.1 µmol/L; Res: 10
µmol/L. Scale bar, 100 µm.
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exons 15 and 16 of WRN alleles, which recapitulates the
major cellular defects of WS, including accelerated senes-
cence, growth arrest, telomere attrition, increased DNA
damage response, excessive production of inﬂammatory
factors, as well as increased stem cell attrition in the in vivo
niche (Zhang et al., 2015). We also identify heterochro-
matin disorganization as a driver for WS MSC aging, and
overexpression of heterochromatin component HP1α can
partially rescue the accelerated aging defects in the WS
MSCs (Zhang et al., 2015). These ﬁndings suggest that
epigenetic alterations could underlie human cellular aging,
and the “epigenetic aging” can be repressed or reversed
under speciﬁc context. It is unknown, however, if the pre-
mature aging processes can be alleviated by chemicals or
drugs.
Here, utilizing the WS MSC model, we tested the potential
rescuing effect with a group of compounds which have been
reported with “anti-aging” or “longevity-promoting” activity
from different model organisms. Among them, Vitamin C
(VC, also known as ascorbic acid) showed the best efﬁcacy
on alleviation of the aging defects in WS MSCs.
RESULTS
Screening for chemicals capable of repressing
accelerated cellular senescence in WS MSCs
Using our recently established WS MSC aging model (Zhang
et al., 2015), we have screened a panel of known anti-oxi-
dants and other chemicals with reported anti-aging effects,
including VC, Vitamin E (VE), (-)-epigallocatechin gallate
(EGCG), N-Actyl-L-cysteine (NAC), Metformin (Met), Rapa-
mycin (Rap), and Resveratrol (Res) (Baur et al., 2006; Cao
et al., 2011; Dallaire et al., 2014; Harrison et al., 2009; La
Fata et al., 2014; Lebel et al., 2010; Martin-Montalvo et al.,
2013; Na et al., 2008). We designed an in vitro screening
platform by using late passage (passage 5) of WRN-/- MSCs
at low conﬂuence. The low cell density allowed for evaluating
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Figure 2. VC represses aging properties in WS MSCs. (A) Growth curve analyzing the population doubling of MSCs. (B) VC
promoted proliferation in WRN-/- MSCs. Representative immunoﬂuorescence staining (left) and quantitative analysis (right) of Ki67 in
vehicle or VC treated (7 days) WT MSCs andWRN-/- MSCs. Scale bar, 50 µm. (C) H2DCFDA based measurement of reactive oxygen
species (ROS) in vehicle or VC treated (7 days) WT MSCs and WRN-/- MSCs. (D) Telomere lengths of WS MSCs with or without VC
treatment were measured by quantitative RT-PCR. (E) Expression of senescence-associated proteins p16Ink4a and GATA4 was
examined by Western blot, and quantitative results were shown on the right. (F) ELISA showing a decrease in IL-6 and IL-8 secretion
in WRN-/- MSCs after VC treatment. The values were normalized by the cell numbers. Data are represented as mean ± SEM, **P <
0.01, ***P < 0.001; n ≥ 3.
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stringent phenotypic rescue and maximizing the efﬁcacy of
chemicals. We treated the cells with the indicated chemicals
up to one week (Fig. 1A). Among all the chemicals included,
we identiﬁed VC as the most potent agent that signiﬁcantly
reduced the frequency of senescence-associated-β-galac-
tosidase (SA-β-gal) positive cells in a dose-dependent
manner (Fig. 1B and 1C). The efﬁcacy of VC on suppressing
senescence was very prominent at physiological concen-
trations starting from as low as 10 µmol/L, relative to the
vehicle treatment group. At the proposed physiological
doses of plasma VC (Du et al., 2012), ranging from 35 to
70 µmol/L, VC exhibited close to the optimal suppressive
effect on senescence (compared between 68% in control
group, 20%–23% in physiological dosages (35–70 µmol/L),
and 10% in optimal dose (280–560 µmol/L) (Fig. 1B). Other
compounds, including VE, EGCG, NAC, Met, Rap, and Res
also showed mild activity in reducing SA-β-gal positive
subpopulation (Fig. 1B and 1C), but the effects were not as
signiﬁcant as VC’s. These results indicate that VC has a
unique activity in repressing accelerated senescence in WS
MSCs.
VC suppresses aging-related parameters
We have shown that the WS MSCs exhibited many features
of premature cellular senescence, such as decreased pro-
liferation, elevated senescence-associated secretory
phenotype (SASP), and heterochromatin alterations etc.
(Zhang et al., 2015). To determine the impact of VC on these
parameters, we treated WS MSCs with VC and examined
different cellular properties related to aging. Consistent with
the reduced premature cellular senescence, VC treatment
reactivated the cellular proliferation potential and upregu-
lated the frequency of Ki67 positive cells (Fig. 2A and 2B).
Reactive oxygen species (ROS) production, as indicated by
the positive staining of H2DCFDA, was signiﬁcantly elevated
in the senescent WS MSCs as previously reported for WS
mouse ﬁbroblasts (Labbe et al., 2010), which was reduced to
a similar level as in the WT MSC cells by VC treatment
(Fig. 2C). In addition, treatment of WS MSCs with VC
repressed accelerated telomere shortening (Fig. 2D) (Zhang
et al., 2015), down-regulated expression of aging markers,
such as p16Ink4a and GATA4 (Fig. 2E) (Kang et al., 2015),
and effectively alleviated SASP, including the production of
pro-inﬂammatory cytokines such as IL-6 and IL-8 (Fig. 2F).
Heterochromatin alteration is one of the hallmarks and is
a driver for WS MSC aging (Lopez-Otin et al., 2013; Zhang
et al., 2015). Western blotting showed that levels of hete-
rochromatin markers HP1α and H3K9me3 were up-regu-
lated upon VC treatment, indicating that VC promotes
remodeling of heterochromatin to a younger state. In line
with the heterochromatin changes, the expression of LAP2β,
the heterochromatin-anchoring inner nuclear membrane





































































































Figure 3. VC restores epigenetic parameters and in vivo viability of WS MSCs. (A) Western blot analysis of the indicated
proteins in MSCs. (B) VC increased heterochromatin markers by immunoﬂuorescence staining. Representative immunoﬂuorescence
staining (left) and quantitative analysis (right) of LAP2β in vehicle or VC treated (7 days) WT MSCs andWRN-/- MSCs. Scale bar, 25
µm. (C) Luciferase activity of WS MSCs was detected by in vivo imaging system (IVIS) one week after implantation, and quantitative
results were shown on the right. All data are represented as mean ± SEM. *P < 0.05, ***P < 0.001 by t test; n ≥ 3.
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found an increase in the number of nuclear foci for γ-H2AX
and phosphorylated ATM/ATR substrates in WRN-deﬁcient
MSCs; VC had no inﬂuence on these foci formation
(Fig. S1A), suggesting a possibility that the restoration of
heterochromatin and nuclear lamina components may not be
associated with alleviation of DNA damage response (DDR)
in WS MSCs. Together, these results indicate that VC is able
to rejuvenate the heterochromatin and nuclear lamina
architectures in WS MSCs, a process independent of the
DNA damage response.
To investigate whether VC can restore the MSC’s in vivo
activity, luciferase-labeled WS MSCs were pre-treated with
VC, and implanted into the tibialis anterior muscle of the
immunodeﬁcient mice, and then engraftment and survival
were determined by measuring luminescence signals after 7
days. In line with the observed repression of accelerated
cellular decay in vitro, VC treatment effectively restored the
in vivo viability of WS MSCs (Fig. 3C).
VC inhibits aging related genes and pathways in theWS
MSC model
To uncover the molecular mechanism underlying how VC
rejuvenates WS MSCs, we performed genome-wide RNA
sequencing (RNA-seq). We identiﬁed 1595 upregulated
genes and 1419 downregulated genes (|log2(Fold change)|
> 1, P value < 0.05) in VC treated WS MSCs relative to
vehicle treated cells (Fig. 4A, S1B–C and Supplementary
tables). Gene Ontology (GO) Term analysis for cellular
component, biological pathways and molecular functions
indicated that the most signiﬁcant pathway
(P value = 0.00036) for the VC-upregulated genes in WS
MSCs was “chromosome organization” (Fig. S1D), which is
also the most signiﬁcant GO term for downregulated genes
in WS MSCs compared to wild-type MSCs (Zhang et al.,
2015). Notably, VC induced the re-expression of chromo-
some-packaging proteins at centromeres in WS MSCs,
which is consistent with a rescue of cellular aging process
(Fig. S1D) (Zhang et al., 2015).
We also analyzed the differentially expressed genes
using KEGG database. We found “cell cycle” as the top
remarkable set of genes upregulated by VC, in agreement
with the increased Ki67 staining as the proliferation index
(Fig. 3B). Consistently, the transcripts for many of these cell
cycle genes are also the ones we initially identiﬁed to be
down-regulated in WS MSCs (Zhang et al., 2015). We
noticed that the molecular network for cell cycle entry was
partially re-activated by VC (Fig. 4B and 4C). Of note, the cell
mitosis-promoting proteins such as PCNA, CDK1, and CDK2
were also signiﬁcantly upregulated in VC-treated WS MSCs
(Fig. 4C and 4D). In addition, we also found that VC was
involved in DNA replication and repair pathways. For
example, VC treatment led to the reactivation of the DNA
replication pathway that was repressed in WRN-deﬁcient
MSCs (Fig. 4B) (Zhang et al., 2015), and of the various DNA
repair pathways including mismatch repair, homologous
recombination, base excision repair, and Fanconi anemia
pathway (Zhang et al., 2015) (Fig. 4B). On the other hand,
VC down-regulated several signaling pathways that are
normally activated during cellular senescence, such as P53,
FoxO, and HIF-1 pathways (Lopez-Otin et al., 2013; Martins
et al., 2015), as well as the pathways related to lysosome
degradation and protein-processing in endoplasmic reticu-
lum (ER) (Fig. 4B). These changes were validated by
quantitative RT-PCR (Fig. 4D). Together, these results
clearly indicate that VC plays a role in re-activation of aging-
suppressing genes and related signaling pathways at the
transcriptional level.
DISCUSSION
The combination of gene editing technique and human
pluripotent stem cells (hPSC) including induced pluripotent
stem cells (iPSCs) and embryonic stem cells offers a new
way to model genetic diseases for studying disease-causing
mechanisms and screening drugs in vitro. Since 2011, we
and others have shown the capacity of hPSC disease
models in recapitulating disease defects in various human
genetic disorders including Hutchinson-Gliford progeria
syndrome (HGPS), Parkinson's diseases, Fanconi Anemia,
xeroderma pigmentosum, glioblastoma, and WS (Cheung
et al., 2014; Duan et al., 2015; Fu et al., 2016; Liu et al.,
2011; Liu et al., 2012a; Liu et al., 2012b; Liu et al., 2014; Park
et al., 2008; Saha and Jaenisch, 2009; Yu et al., 2013;
Zhang et al., 2015). We have also provided evidence
showing that these disease models could be used to
examine the functional effects of chemical compounds as
well as to re-purpose the old drugs already approved for
different diseases in clinics. In this study, we identify VC as a
potent agent to alleviate aging process in a stem cell model
for adult progeria. Among the compounds we tested, VC has
the most signiﬁcant effect on repressing cellular senescence
(indicated by SA-β-gal staining) and on promoting the WS
MSC growth. For example, whereas the mTOR inhibitor
rapamycin has been reported to improve the proliferation
potential in HGPS ﬁbroblasts (Cao et al., 2011), it showed
marked repressive effect on the self-renewal of WS MSCs
(Fig. 1B, 1C and data not shown). VC effectively represses
the accelerated cellular senescence, improves the stem cell
self-renewal, decreases SASP in WS MSCs, and alleviates
telomere attrition. This ﬁnding is of great interest because
previous studies on C. elegans and mouse models have
showed that a continuous long-term treatment of WS indi-
viduals with high doses of VC is a promising therapeutic
approach for this syndrome (Dallaire et al., 2014; Lebel et al.,
2010). Our study, together with evidences from C. elegans
and mouse models, provides an important cue to WS ther-
apy. Recent study indicated that the blood of WS patient has
increased level of IL-6 (Davis and Kipling, 2006). Consis-
tently, our WS stem cell model recapitulated the upregulation
RESEARCH ARTICLE Ying Li et al.
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of IL-6, a phenotype of SASP, in the medium of WS MSC
cultures (Zhang et al., 2015). We also identify that VC
decreases the IL-6 secretion in WS MSCs. This suggests a
possibility of employing VC as a beneﬁcial factor to decrease
the inﬂammatory mediators for WS patients. Given that VC
restores the in vivo viability of WS MSC, one may expect that
VC could help to eliminate the harmful effects of senescent
cells and/or counteract the premature stem cell deterioration
in vivo (Baker et al., 2016; Baker et al., 2011). Although
human unlike rodents cannot synthesize VC in the body, the
water-soluble property of VC makes it very easy to be sup-
plied through dietary sources and supplements. Our study
shows that high concentrations of VC (i.e. 280 µmol/L) pro-
duce the best effect on rejuvenating WS MSCs without dis-
cernible cytotoxicity (Du et al., 2012). Oral supplement of VC
normally reaches micromolar level in the plasma, with the
highest plasma concentration around 80 µmol/L, which is the
suboptimal dose for alleviating the aging process. However,
in clinical trials of cancer therapy, intravenous injection of VC
can increase the plasma level of VC up to millimolar levels
(Du et al., 2012; Fukushima and Yamazaki, 2010). Thus, it
would be of particular interest to titrate the optimal dosage of
VC used in clinics from which WS patients will beneﬁt mostly.
One concern is that higher level of VC tends to induce free
radicals, a phenotypic switch from anti-oxidant to oxidizing
agent (Du et al., 2012). Thus the titration for optimal VC
concentration in human patients needs to be very cautiously
performed.
Regarding the molecular mechanism, we found that
treatment with VC effectively diminishes cellular ROS in WS
MSCs. This could be one of the molecular mechanisms
underlying VC’s effect, given that WS MSCs exhibit much
higher ROS levels than their wild-type counterparts. We
found that, besides VC, other ROS eliminators also show an
effect on the rejuvenation of WS MSCs. For example, NAC,
a strong antioxidant, and Met and EGCG, activators of NRF2
antioxidant pathway (Martin-Montalvo et al., 2013; Na et al.,
2008), all alleviated the aging defects of WS MSCs. One
would postulate that an increased anti-oxidizing capability in
WS MSCs could principally counteract the harmful effect of
ROS on compromising the biomacromolecule machinery
(i.e. DNA or protein) inside the cells. On the other hand,
elevated ROS levels have recently been known as a factor
leading to heterochromatin disorganization (Frost et al.,
2014). In this context, reduction of ROS levels may provide
an explanation for restoration of heterochromatin architec-
ture by VC. However, it should also be noted that NAC, a
much stronger antioxidant, only show mild rescue activity
towards WS MSCs. Therefore, this raises a possibility that
VC may also exert an effect in a ROS-scavenger indepen-
dent manner. Recent evidence points to a more direct role of
VC in regulating epigenetic reprogramming (Young et al.,
2015). For instance, VC functions as a cofactor for TET
dioxygenases that catalyze the oxidation of 5-methylcytosine
(5mC) to 5-hydroxymethylcytosine (5hmC), further resulting
in the generation of 5-formylcytosine (5fC), 5-carboxylcy-
tosine (5caC), and unmodiﬁed cytosine. In addition, VC
serves as a cofactor of the JumonjiC (JmjC)-domain con-
taining histone demethylases (i.e. JHDM1) (Chen et al.,
2013; Esteban and Pei, 2012; Esteban et al., 2010; Pera,
2013; Wang et al., 2011; Yulin et al., 2012). A more direct
evidence is that VC promotes proliferation of bone marrow-
derived MSCs and facilitates the derivation of iPSCs from
MSCs (Yulin et al., 2012). How VC coordinates different
mechanisms in alleviating aging defects in WS MSCs war-
rants further investigation.
In addition, consistent with a role of VC in rejuvenating the
nuclear lamina and heterochromatin in WS MSCs, our study
revealed that VC reset the gene expression proﬁles of WS
MSCs to a younger state. Our recent study has indicated that a
group of genes linked to chromatin condensation, cell cycle,
DNA replication, and DNA repair were all repressed in WS
MSCs (Zhang et al., 2015). Intriguingly, parts of these genes
were reactivated by VC treatment in WS MSCs. These obser-
vations veriﬁed that VC has the capability to help WSMSCs to
reprogram the senescent transcriptome probably by reactivat-
ing the stemness-associated core transcriptional network.
Moreover, our study also demonstrate that VC treatment can
downregulate pro-senescence pathways, including P53,
FoXO, and HIF etc., which may provide another layer of
mechanisms in recovering young MSC phenotypes (Fig. 5).
MATERIALS AND METHODS
Cell lines generation, culture and treatment
WRN gene knockout human ESC clones (referred to as WRN-/--
ESC) were generated as previously described (Zhang et al., 2015).
Differentiation, puriﬁcation, culture, and characterization of WT-ESC
and WRN-/--ESC derived mesenchymal stem cells (MSCs) were
performed as described previously (Zhang et al., 2015).
Procedure of cell treatments with chemicals at indicated con-
centrations was illustrated in Fig. 1A, including Vitamin C (VC,
Figure 4. VC induced a global transcriptome change of
aging-suppressing genes and pathways. (A) Volcano plot
showing signiﬁcantly altered genes (|log2(Fold change)| > 1,
P value < 0.05) between vehicle- and VC-treatedWRN-/- MSCs.
FC, fold change. (B) KEGG based pathway enrichment analysis
of the signiﬁcantly altered gene sets (green: down regulated
genes; red: up regulated genes) in WRN-/- MSCs upon VC
supplement. Number of altered genes in each pathway was
indicated by size of the bubble. (C) Predicted protein-protein
interactions (PPI) analysis of differentially expressed genes was
based on the STRING database, according to e-value = 1 ×
10−10 and string score > 700, differentially expressing genes
with interaction frequency > 80 were illustrated on the picture.
Node size indicated the degree of interaction and node color
indicated clustering co-efﬁciency (green: down regulated
genes; red: up regulated genes). (D) Heatmap of mRNA levels
between vehicle- and VC-treated WRN-/- MSCs.
b
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Sigma, A4403), (-)-epigallocatechin gallate (EGCG, Sigma, E4143),
Vitamin E (VE, Sigma, T1782), N-Actyl-L-cysteine (NAC, Sigma,
A7250), Metformin (Met, Tocris, 2864), Rapamycin (Rap, Tocris,
1292), and Resveratrol (Res, Sigma, R5010). VC and NAC were
dissolved in water. All other compounds were dissolved in DMSO.
Final concentrations of DMSO did not exceed 0.1%.
Reagents
Antibodies were purchased from the following companies.
Abcam: anti-H3K9me3 (ab8898); Santa Cruz Biotechnology: anti-
β-actin (SC-130301), anti-GATA4 (SC-1237); Cell Signaling
Technology: Phospho-(Ser/Thr) ATM/ATR Substrate Antibody
(2851), anti-HP1α (2616), anti-p16 (4828); Millipore: anti-γ-H2AX
(05-636); BD Bioscience: anti-LAP2β (611000); Vector: anti-Ki67
(VP-RM04).
Senescence associated β-galactosidase (SA-β-gal) staining
SA-β-gal staining was performed as described previously (Debacq-
Chainiaux et al., 2009). Brieﬂy, cultured cells were washed in PBS
and ﬁxed at room temperature for 3 min in 2% formaldehyde and
0.2% glutaraldehyde. Fixed cells were stained with fresh staining
solution for SA-β-gal activity at 37°C overnight, and counted for
positivity (N > 300).
ROS detection
Oxidative stress levels were quantiﬁed through H2-DCFDA (Invit-
rogen, C6827) based ﬂow cytometry following manufacturer’s
instructions
ELISA
Kits to detect IL-6 (D6050) and IL-8 (D8000C) were purchased from
R&D Systems, and used as previously reported (Zhang et al., 2015).
All ELISA data were normalized to cell numbers
Population doubling time (PDT)
Cell numbers of each passage were counted by hemocytometer
after trypan blue staining, and then PDT was calculated according to
previous formulae (Zhang et al., 2015)
Western bloting and quantitative RT-PCR
For Western blot, preparation of lysate from cell culture was described
as previously reported. BCA kit purchased from Thermo Fisher Sci-
entiﬁc was used for protein quantiﬁcation. Equal amounts of protein
lysates were subjected to the wells of the SDS-PAGE gel, and then
electrotransferred to a PVDF membrane. After blocking, the mem-
brane was incubated with appropriate dilutions of primary antibody
and secondary antibodies (Jackson ImmunoResearch Labs). Then
imaging was performed using ChemiDoc XRS system (Bio-Rad).
For quantitative analysis of gene expression, total RNA was
extracted according to previous protocol (Zhang et al., 2015). Then
cDNA was synthesized by GoScript™ Reverse Transcription Sys-
tem (Promega), followed by removal of genomic DNA with DNA-
free™ Kit from Ambion. Quantitative RT-PCR was performed using
SYBR® Green Supermix (TOYOBO). Quantitative PCR-based
method was used to measure telomere length according to estab-
lished protocol (Zhang et al., 2015). Primer sequences are listed in
Table S1.
Immunoﬂuorescence microscopy
Cells were washed once with PBS and ﬁxed in 4% formaldehyde at
room temperature. Subsequently, cells were blocked with 10% don-
key serum and 0.1% Triton X-100 in PBS for 1 h, and then diluted
primary antibodies were added and incubated at 4°C overnight. After
three consecutive washes in wash buffer, cells were incubated for 45
min with secondary antibodies (Alexa Fluor Donkey-anti-mouse and
Alexa Fluor Donkey-anti-rabbit, Invitrogen) together with Hoechst
33342 (Invitrogen). After washed, samples were covered with VEC-
TASHIELD mounting medium (Vector) and imaged in Leica SP5
confocal. Acquisition parameter was same for each experiment.
Around 100 randomly selected cells were analyzed.
In vivo cell viability analysis
MSC implantation was performed as previously described (Zhang
et al., 2015). In brief, 5 × 105 luciferase-expressing WS MSCs were
pretreated with vehicle or 280 μmol/L VC for one week and then
implanted into the middle of the tibialis anterior muscle of immun-
odeﬁcient mice. Seven days after implantation, mice were anaes-
thetized and injected with D-luciferin solution. Fifteen minutes later,
in vivo luciferase activity of each mouse was determined by the IVIS
lumina system (PerkinElmer). Luminescence intensity was normal-
ized to luciferase intensity of MSCs just before implantation. Animal
experiments performed in this study were approved by the Institute
of Biophysics, Chinese Academy of Science.
RNA-seq library construction
Two million cells were applied to extract total RNA as previously
described (Zhang et al., 2015). RNA integrity was assessed using
the RNA Nano 6000 Assay Kit of the Bioanalyzer 2100 system
WS-MSC
1.Reactivated proliferative potential 
4.Decreased senescence-associated secretory phenotype (SASP) 











2.Repressed expression of p16lnk4a and GATA4
6.Restored the in vivo viability
3.Alleviated telomere attrition
Figure 5. A proposed model illustrating that VC represses
aging properties in WS MSCs by causing a global transcrip-
tome change of aging-suppressing genes and pathways.
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(Agilent Technologies). A total amount of 3 μg RNA per sample was
used as input material. For the RNA sample preparations,
sequencing libraries were generated using NEBNext® Ultra™ RNA
Library Prep Kit for Illumina® (NEB) following manufacturer’s rec-
ommendations and index codes were added to attribute sequences
to each sample. Then, PCR products were puriﬁed (AMPure XP
system) and library quality was assessed using the Agilent Bioan-
alyzer 2100 system. At last, the library preparations were sequenced
on an Illumina Hiseq platform and 125 bp/150 bp paired-end reads
were generated.
RNA-seq data analysis
Then reads were mapped to the human reference genome hg19
(from UCSC) by TopHat v2.0.12. Transcript expression and differ-
entially expressed genes were analyzed as previously reported (Wu
et al., 2015). Brieﬂy, HTSeq v0.6.1 was used to count the reads
numbers mapped to each gene. And then FPKM (Fragments per
kilobase of transcript sequence per millions) of each gene was
calculated based on the length of the gene and reads count mapped
to this gene. Differential expression analysis of two groups (two
biological replicates per condition) was performed using the DESeq
R package (1.18.0). Gene Ontology (GO) enrichment analysis of
differentially expressed genes was implemented by the GOseq R
package, in which gene length bias was corrected. KOBAS software
was used to test the statistical enrichment of differential expression
genes in KEGG pathways. GO terms and pathway enrichment with
corrected P value less than 0.05 were considered signiﬁcantly
enriched by differential expressed genes. Protein-protein interac-
tions (PPI) prediction of differentially expressed genes was based on
the STRING database.
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